Economic Evaluation of Three Two-Drug Chemotherapy Regimens in Advanced Non-Small-Cell Lung Cancer

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.23, Iss.11, 2005-01, pp. : 1155-1166

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Advances in chemotherapy in advanced non-small-cell lung cancer

By Maione Paolo Rossi Antonio Sacco Paola Claudia Bareschino Maria Anna Schettino Clorinda Gridelli Cesare

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 18, 2010-12 ,pp. : 2997-3007

Informa Healthcare

Access to resources Recommend Favorite

Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?

By Giovannetti Elisa Toffalorio Francesca De Pas Tommaso Peters Godefridus J

Pharmacogenomics, Vol. 13, Iss. 9, 2012-07 ,pp. : 1073-1086

Future Medicine

Access to resources Recommend Favorite

Combination Chemotherapy with Docetaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer

By Schuette W.

Clinical Drug Investigation, Vol. 21, Iss. 3, 2001-03 ,pp. : 161-168

Adis International

Access to resources Recommend Favorite

Axitinib for the treatment of advanced non-small-cell lung cancer

By King Judy W

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 6, 2013-09 ,pp. : 765-773

Informa Healthcare

Access to resources Recommend Favorite

Afatinib for the treatment of advanced non-small-cell lung cancer

By Genova Carlo Rijavec Erika Barletta Giulia Burrafato Giovanni Biello Federica Dal Bello Maria Giovanna Coco Simona Truini Anna Alama Angela Boccardo Francesco Grossi Francesco

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 6, 2014-04 ,pp. : 889-903

Informa Healthcare

Access to resources Recommend Favorite